Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Generic · Tablet

Deferasirox 180 mg tablet price what pharmacies pay, and what you should

There is no weekly pharmacy acquisition cost for deferasirox 180 mg tablet this week. The makers, package codes, recalls and label are below.

What did you pay for deferasirox 180 mg tablet? Share it.

Every price shared helps the next person know what's fair - and shows which pharmacies charge the least. Anonymous, 30 seconds.

How were you treated? optional

Free, anonymous, no sign-up. Please don't include personal or health details. Community rules.

Supply status: shortages & recalls

No shortage reportedChecked Nov 17, 2026
1 ongoing recall1 recall on record, latest Nov 15, 2023

Recalls

A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.

Every manufacturer and package code

7 companies sell deferasirox 180 mg tablet under 7 package codes (NDCs).

All 7 package codes

A dash means no weekly price for that maker's packages. Which maker your pharmacy stocks usually doesn't change what you pay, but you can ask.

Other deferasirox strengths and forms

Strength and formPer unitPharmacies pay4 weeks52 weeks
360 mg tablet$1.12$33.58 / 30 tablets-10.3%-11.7%
500 mg tablet for oral suspension$5.85$175.57 / 30 tablets

Official label & what changed

Last changedDecember 4, 2024
Version5 of 4
EffectiveSep 30, 2024
Read the label

These highlights do not include all the information needed to use DEFERASIROX TABLETS safely and effectively. See full prescribing information for DEFERASIROX TABLETS. DEFERASIROX tablets, for oral use Initial U.S. Approval: 2005

This drug has a boxed warning

WARNING: RENAL FAILURE, HEPATIC FAILURE, AND GASRTOINTESTINAL HEMORRHAGE

Renal Failure

Deferasirox can cause acute renal failure and death, particularly in patients with comorbidities and those who are in the advanced stages of their hematologic disorders.

Evaluate baseline renal function prior to starting or increasing deferasirox dosing in all patients. Deferasirox is contraindicated in adult and pediatric patients with eGFR less than 40 mL/min/1.73 m2. Measure serum creatinine in duplicate prior to initiation of therapy. Monitor renal function at least monthly. For patients with baseline renal impairment or increased risk of acute renal failure, monitor renal function weekly for the first month, then at least monthly. Reduce the starting dose in patients with preexisting renal disease. During therapy, increase the frequency of monitoring and modify the dose for patients with an increased risk of renal impairment, including use of concomitant nephrotoxic drugs, and pediatric patients with volume depletion or overchelation [see Dosage and Administration (2.1, 2.4, 2.5), Warnings and Precautions (5.1), Adverse Reactions (6.1, 6.2)].

Hepatic Failure

Deferasirox can cause hepatic injury including hepatic failure and death.

Measure serum transaminases and bilirubin in all patients prior to initiating treatment, every 2 weeks during the first month, and at least monthly thereafter.

Avoid use of deferasirox in patients with severe (Child-Pugh C) hepatic impairment and reduce the dose in patients with moderate (Child-Pugh B) hepatic impairment [see Dosage and Administration (2.4), Warnings and Precautions (5.2)].

Gastrointestinal Hemorrhage

Deferasirox can cause gastrointestinal (GI) hemorrhages, which may be fatal, especially in elderly patients who have advanced hematologic malignancies and/or low platelet counts.

Monitor patients and discontinue deferasirox for suspected GI ulceration or hemorrhage [see Warnings and Precautions (5.3)].

WARNING: RENAL FAILURE, HEPATIC FAILURE, AND GASTROINTESTINAL HEMORRHAGE

See full prescribing information for complete boxed warning.

Deferasirox may cause serious and fatal:

acute kidney injury, including acute renal failure requiring dialysis and renal tubular toxicity including Fanconi syndrome (5.1)

hepatic toxicity, including failure (5.2)

gastrointestinal hemorrhage (5.3)

Deferasirox therapy requires close patient monitoring, including laboratory tests of renal and hepatic function. (5)

We check this label every day. When it changes, the sections that changed appear here, old text beside new.

We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.

Questions about deferasirox 180 mg tablet

Who makes deferasirox 180 mg tablet?

7 companies: Alembic Pharmaceuticals Inc., Aurobindo Pharma Limited, Camber Pharmaceuticals, Inc., Dr. Reddy's Laboratories Inc, NorthStar Rx LLC, Xiromed, LLC, Zydus Pharmaceuticals USA Inc.. See every package code.

Is deferasirox in shortage?

No shortage is reported right now. We check every day.

Has deferasirox been recalled?

1 recall on record, 1 ongoing. Recalls name specific lots - check yours.

What does "pharmacies pay" mean?

It's the national average price retail pharmacies pay wholesalers and makers to buy the drug, from a weekly government survey of pharmacy invoices. It doesn't include the pharmacy's costs of filling a prescription, which is why the fair price adds a margin and a dispensing fee. How we work it out.

Talk about deferasirox 180 mg tablet

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.